Brief: Senti Biosciences Q4 Net Income USD -14.467 Million
27/03/2026 12:00
Mar 27 (Reuters) - Senti Biosciences Q4 revenue USD 22 thousand. Q4 EPS USD -0.53 Q4 operating expenses USD 18.658 million Q4 operating income USD -18.636 million
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates